Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. - Wikidata - awgldk - TriplyDB

Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.

Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.

http://www.wikidata.org/entity/Q37343752

about

Treatment of Drug Susceptible Pulmonary Tuberculosis Immunogenicity without Efficacy of an Adenoviral Tuberculosis Vaccine in a Stringent Mouse Model for Immunotherapy during Treatment Assessment of treatment response in tuberculosis Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis.Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.Prevalence of extended treatment in pulmonary tuberculosis patients receiving first-line therapy and its association with recurrent tuberculosis in Beijing, China.Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa.Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs.The Extracellular Matrix Regulates Granuloma Necrosis in Tuberculosis.Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis.Urine lipoarabinomannan to monitor antituberculosis therapy response and predict mortality in an HIV-endemic region: a prospective cohort study.Clinical symptoms and microbiological outcomes in tuberculosis treatment trials.Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update Intermittent Versus Daily Pulmonary Tuberculosis Treatment Regimens: A Meta-Analysis.A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets Smoking and 2-month culture conversion during anti-tuberculosis treatment Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy.Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response.Plasma Biomarkers Can Predict Treatment Response in Tuberculosis Patients: A Prospective Observational Study.Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques.Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations.Update in tuberculosis 2009.Immunological biomarkers of tuberculosis.PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis.Emerging drugs and alternative possibilities in the treatment of tuberculosis.Mathematical Models of Tuberculosis Reactivation and Relapse Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response.Effect of Intermittency on Treatment Outcomes in Pulmonary Tuberculosis: An Updated Systematic Review and Metaanalysis.Challenges of Phase III study design for trials of new drug regimens for the treatment of TB.Time until relapse in tuberculosis treatment trials: implication for phase 3 trial design.[Adverse effects of the new tuberculosis treatment regimen recommended by the Brazilian Ministry of Health].Pretreatment time to detection of Mycobacterium tuberculosis in liquid culture is associated with relapse after therapy.Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis.Evaluation of serum inflammatory biomarkers as predictors of treatment outcome in pulmonary tuberculosis.Effect of efflux pump inhibitors on the susceptibility of Mycobacterium tuberculosis to isoniazid.Antimycobacterial drug discovery using Mycobacteria-infected amoebae identifies anti-infectives and new molecular targets.

P2860

Q26801605-0D27E7DD-1CE5-44DA-BE92-CCC4F37C5766 Q27306144-E59446E9-D637-43E7-A08E-7ADAAEC95EE7 Q28384421-80CE52FB-F22F-494D-A0E7-7431F959A499 Q28391110-AAD75B28-F78A-4AC1-8329-303CB45975E3 Q28729980-8128A63B-867C-4E78-9F71-0CB571F03C51 Q33590272-9A60A2A2-87FA-4FE1-93D3-EAC7B2E4C4CD Q33723589-8C67BC91-9A87-4D4B-99D6-F900508749AA Q33761869-F0C8D761-1371-45B4-83E8-9B6206971481 Q33873368-6912D679-077D-441B-AD1A-733D4BCFCD26 Q33947806-1AB4BED6-AD96-4A28-8A59-8E60BF521BDF Q34462437-B714EECA-5C43-4B0B-9974-A983DC0DE079 Q34981779-0FF57675-C30A-4A52-8834-6A4006A1AF78 Q35166484-C495081E-A868-47D5-BDF6-2945A7A302BC Q35466103-1F8DA539-6DD6-4643-B513-888B868DE865 Q35549242-42171761-B378-4D29-A9F4-0B48FCAE1F00 Q35617686-AA9C23E5-0131-471D-A0E0-2A8481189248 Q35657670-D95C46DE-5957-4C5C-97D7-5169FCDD9287 Q35745991-F2C0B9C6-164C-46CA-96C3-DBF54C8146A6 Q35835697-4446C1E1-3B07-4857-B6A4-35DFBF468221 Q35983023-25BA1BCB-DD2F-4620-984D-1A0CD7F03864 Q36115081-E175B026-4A17-460B-BE35-F88C71B4F37A Q36136779-1EE221C7-018F-4A10-9C44-30E54D064E51 Q36195750-10F1DE79-E431-42B3-BAB6-4944D3BD4331 Q36212962-DEC1C1A4-836C-4776-866D-732AA5187EB6 Q37385024-8CD677A6-A0A3-4751-80E4-AF55DDF49F9A Q37704062-B60F4E1F-A156-436A-8AE0-78A86F46FDB8 Q37862987-04BED946-E82F-4A0A-8AD4-8DA94ECB818B Q38393463-4527CDB1-7145-4941-9975-04B2D29FDABA Q38724073-45ED441D-7F66-4EC3-B30D-7F521AE90972 Q38848891-73C87A17-98FF-4827-ADF8-57BDEB8E65E5 Q38948899-E86A5534-E58A-43C6-A53B-131E882733E0 Q38958884-86F435DD-1D26-4AAF-9854-05F3705873E1 Q39769344-66FB4031-D17D-4BC0-BE48-9FAA759A57DF Q42325641-7D7F5842-BC6C-4D52-B8D1-A3AC2F876E54 Q43058967-435D886A-DF06-45A7-98F9-53B12E242325 Q43061386-19739BB2-1097-4C7D-A142-E7033A93051C Q43608012-918CD1C0-1B53-468B-A36B-13D2D4DD54ED Q47139711-31032523-C471-4E47-A676-D334E04336A0 Q47146402-401E44FD-8E11-419E-87EE-C362C2334B2E Q52676415-36B9DD1F-1756-41D4-950B-C8D0CA5954A9

P2860

Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.

http://www.wikidata.org/entity/Q37343752

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Shortening treatment in adults ...... nd 2-month culture conversion.

@en

Shortening treatment in adults ...... nd 2-month culture conversion.

@nl

type

label

Shortening treatment in adults ...... nd 2-month culture conversion.

@en

Shortening treatment in adults ...... nd 2-month culture conversion.

@nl

prefLabel

Shortening treatment in adults ...... nd 2-month culture conversion.

@en

Shortening treatment in adults ...... nd 2-month culture conversion.

@nl

P1433

Q37343752-5A8B15D8-3733-48B0-B50D-6A4177234BB0

P1476

Q37343752-FA4E4CFF-CD86-4FC3-8A0E-454BDD905F2D

P2093

Q37343752-0C684F88-07D0-4E28-BA5E-EE0224056A78

Q37343752-1050C543-6288-4D84-AA3E-C4E22BA8713E

Q37343752-188F65ED-1676-4B83-9853-3CA489E37A80

Q37343752-23A3DF65-2187-40BD-B4C3-7B7F215C0924

Q37343752-26520340-AFC5-4BE1-8E83-CFFB9C8D7FE7

Q37343752-2FCE1BF6-AE74-4355-93DA-78F13E56016F

Q37343752-41645785-CC27-4B86-AF38-A7208A1A90E9

Q37343752-462029CD-4A2D-4925-AD8A-6C89CCA1DF03

Q37343752-54DA32CF-1218-43B1-801D-62298AEE4241

Q37343752-911EEA9E-8ACF-47BD-A915-52EA9FF33938

P2860

Q37343752-195534F0-9669-4C5F-AE5E-FA7791D7C292

Q37343752-1CA031B1-2519-4141-AD5A-E04FDF82AE5A

Q37343752-20C96975-E156-4525-96F2-3832FF007B6A

Q37343752-21079660-7041-4A45-A0D5-B3B264B81D55

Q37343752-23C872DC-D6E4-4303-B551-93BF0A9EBF57

Q37343752-3769FB6C-BBA9-4614-A583-F9E78BBDD2AF

Q37343752-3D2B0328-5476-416B-BC89-90C81DC3E8DC

Q37343752-55F12031-4724-4AA4-AA22-08D17DAD86C4

Q37343752-62E8AC1E-65DE-4268-82DD-4B9B83B1389A

Q37343752-80ACBCFF-FACA-4CE0-99AC-1B0153907474

P304

Q37343752-1D88BC3B-A484-48EE-821C-3516B1C97F54

P31

Q37343752-91A87D4D-D36E-4BD3-B9CE-6CFC42C1C75A

P356

Q37343752-90D73691-53FC-4F71-885F-5A7F3ADAB25F

P407

Q37343752-21C1FB4A-41C4-466B-9FD9-8F682378703B

P433

Q37343752-890BCD77-6710-4179-8E0C-F147455BAA29

P478

Q37343752-027E97CA-0174-4598-93C3-608E971E29DB

P50

Q37343752-36AA01C2-A332-4B11-BDC8-3A1B15F19E12

Q37343752-F9450800-711A-4709-ABBA-F2B0A20CC3C8

P577

Q37343752-D91659D1-EC89-447D-A0C3-14873724F871

P698

Q37343752-8C47974D-27DE-4448-8ED5-1583B635E0C1

P921

Q37343752-4FC25E48-FE6D-47FA-8B6B-5236BD6C368E

P932

Q37343752-455E25AE-76DB-40D5-BDC7-8831F29D191F

P356

RCCM.200904-0536OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Shortening treatment in adults ...... and 2-month culture conversion

@en

P2093

Alphonse Okwera

http://www.w3.org/2001/XMLSchema#string

Barrett Sewali

http://www.w3.org/2001/XMLSchema#string

David Jamil Hadad

http://www.w3.org/2001/XMLSchema#string

John L Johnson

http://www.w3.org/2001/XMLSchema#string

Kathleen D Eisenach

http://www.w3.org/2001/XMLSchema#string

Libby Horter

http://www.w3.org/2001/XMLSchema#string

Maria Imelda Quelapio

http://www.w3.org/2001/XMLSchema#string

Mary Rose Alcaneses

http://www.w3.org/2001/XMLSchema#string

Phineas Gitta

http://www.w3.org/2001/XMLSchema#string

Roy D Mugerwa

http://www.w3.org/2001/XMLSchema#string

P2860

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice

The Garrod Lecture. Understanding the chemotherapy of tuberculosis--current problems

An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence

Diarylquinolines target subunit c of mycobacterial ATP synthase

A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen.

USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results.

Four-month chemotherapy in the treatment of smear-negative pulmonary tuberculosis: results at 30 to 60 months.

Pulmonary tuberculosis: relationship between sputum bacilloscopy and radiological lesions.

Tuberculosis - metabolism and respiration in the absence of growth.

Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis.

P304

558-563

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200904-0536OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

180

http://www.w3.org/2001/XMLSchema#string

P50

Reynaldo Dietze

Ethel Leonor Noia Maciel

P577

2009-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19542476

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

2742745

http://www.w3.org/2001/XMLSchema#string